Bicycle Therapeutics develops precision-guided therapeutics to target solid tumor cancers and other therapeutic applications. The company aims to create impactful medicines to address unaddressed medical needs.

Bicycle Therapeutics

Domain Not Resolving

HSTS

Font Awesome

DNSSEC

reCAPTCHA

reCAPTCHA v2

COVID-19

Mobile Optimized

Akamai Hosted

Adobe Dynamic Tag Management

President and Chief Financial Officer; Board Member, Bti

Lee Kalowski

Chief Scientific Officer

Nicholas Keen

Vice President Chemistry, US

Kevin Mcdonnell

VP, Head of Biometrics

Lei Xu

Healthcare

Phil Brandish

VP, Translational Oncology and Diagnostics

Steve Blakemore

VP Finance

Travis Thompson

Associate Director Regulatory Operations

Abby Cottage

Associate Director, Clinical Scientist

Amy Dickson

Finance and Administration

Amy Garbarino

Carolyn Ng

Bruce Booth

Anja König

Gregory Winter

James Lee

Kevin Lee

Chief Executive Officer

Michael Skynner

Chief Operating Officer

Nick Keen

Ros Deegan

President and Chief Business Officer

Scientific Founders

Christian Heinis

Alethia Young

Chief Financial Officer

Judy Chuk

Head of US Operations

Therapeutics Companies that Exited

United Kingdom Public Companies With More Than $50M in Revenue

Biotechnology Public Companies With More Than $50M in Revenue

Therapeutics Companies (Top 10K)

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Post-IPO Equity - Bicycle Therapeutics

Debt Financing - Bicycle Therapeutics

Series B - Bicycle Therapeutics

Innovate UK

Grant - Bicycle Therapeutics

Vertex Ventures

Series A - Bicycle Therapeutics

Cambridge

Cambridgeshire

United Kingdom

Europe

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Bicycle Therapeutics focuses pipeline and streamlines leadership team

Bicycle Therapeutics Shares Rise 15% on $555M Expected from Private Placement Deal

Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M

Bicycle Therapeutics First Quarter 2024 Earnings: Beats Expectations

Bicycle Therapeutics advances drugs pipeline and extends cash runway into 2026

Cambridge firm in $555m private placement equity financing

United States

North America

Philippines

Asia

India

Cyprus

Hong Kong

HTML5

Google Analytics

Google Fonts

GlobalSign

GreenSock Animation Platform

Google Drive

Amazon Route 53

Google Maps API

Apache Server

Wordpress

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics plc

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 17, 2024 6:05 AM	a16de56a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 17, 2024 6:05 AM	217c0e34
crunchbase trigger	general	Oct 28, 2024 1:51 PM	ca8db934
crunchbase profile	general	Oct 28, 2024 4:56 PM	36025862
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	954d2e92
peers	general	Sep 17, 2024 6:05 AM	283d50a8
news basic	general	Sep 17, 2024 6:05 AM	1947cfde
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:BICYCLETHERAPEUTICS

Bicycle Therapeutics

Last Close

12.49

14/02 21:00

Market Cap

895.71M

Beta: -

Volume Today

146.14K

Avg: -